Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is attractive because its post-consumer separation business is now concentrated in higher-quality Innovative Medicines and MedTech franchises, improving focus, productivity, and margin potential across a global platform serving 350MM patients annually. The drug portfolio is supported by strong momentum in immunology, oncology, and neuroscience, with Tremfya, Darzalex, Icotyde, Caplyta, and Spravato helping offset Darzalex pricing headwinds in EMEA and Stelara erosion, while the pipeline still offers five +$5B and 12 +$1B revenue opportunities. Its MedTech base adds diversification and growth optionality, and management expects 2027 sales growth to be similar to 2026 after adjustments, with EPS growth trending ahead of sales growth, reinforcing the view of a defensive, cash-generative compounder.

Bears say

Johnson & Johnson is facing a negative outlook because its organic revenue growth looks vulnerable to lower-than-expected innovative medicine pipeline contributions, faster loss of exclusivity on key drugs such as Stelara and Xarelto, and uncertain traction from assets like Tremfya, Carvykti, Rybrevant, TARIS, nipocalimab, and milvexian. MedTech is also a risk as competitive headwinds, surgical robotics uncertainty, and weaker product uptake could limit growth, while management has already trimmed FY OpM guidance to about 75bps below 2025 after Firefly and Sail. On top of that, ongoing talc and other product-liability litigation, higher settlement costs, M&A integration risk, and drug-pricing pressure could further erode margins and cash flow.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Oct 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.